+32 1658 9045
0032 (0)16 41 44 07
+32 1650 9045
Av. de l' Armée 68
tel 01 43 25 01 50
fax01 43 25 01 60
9, rue Lagrange
tel 02 36 00 65 93
fax 02 36 00 65 94
tel +32 1658 9045
fax +32 1650 9045
Tel 058 710 33 44
Fax 00 32 16 50 90 45
ul. Grunwaldzka 88A/2
tel +81 78 386 0860
fax +81 78 306 0296
Česká republika Praha
US New York
0032 (0)16 41 44 07
Recombinant Human Interleukin-10 (IL10)
(Cat. No.: C027)
Interleukin-10 is produced by murine T-cells following their stimulation by lectins. The main source for B-cell-derived Interleukin-10 in mice is Ly-1 B-cells that express CD5 and CD11. Murine keratinocytes also produce IL10.
In humans IL-10 is produced by activated CD8 (+) peripheral blood T-cells, by T-helper CD4 (+) T-cell clones (resembling Th0, Th1, and Th2) after both antigen-specific and polyclonal activation, by B-cell lymphomas, and by monocytes following cell activation by bacterial lipopolysaccharides and mast cells. B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of IL-10 into the conditioned medium. The synthesis of IL-10 by monocytes is inhibited by IL-4 and IL-10.
Recombinant Human IL-10 produced in E. coli is a single, non-glycosylated polypeptide chain containing 160 amino acids and having a molecular mass of 18648 Dalton.
Biological Activity: The ED50 as determined by the dose-dependant co-stimulation with murine IL-4 of MC-9 cells was found to be < 2ng/ml, corresponding to a Specific Activity of 1.5 x 106 IU/mg.
Purity: Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
Amino-Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Gly-Gln-Thr.
Endotoxin: Less than 0.1 ng/µg (IEU/µg) of rHuIL-10.
Formulation: The protein was lyophilized from a concentrated (1mg/ml) solution containing 60mM PBS pH-6.5 and 100mM NaCl.
Storage: Lyophilized rHuIL-10 although stable at room temperature for 3 weeks, should be stored desiccated below -18oC. Upon reconstitution rHuIL-10 should be stored at 4oC between 2-7 days and for future use below -18oC. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.
Reconstitution: It is recommended to reconstitute the lyophilized rHuIL-10 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
1: World J Biol Psychiatry 2009
Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey.
[Abstract] Schizophrenia is one of the most severe psychiatric disorders, with a worldwide incidence of 1%. Immunological abnormalities have been found to be associated with schizophrenia for decades. Cytokines are key proteins involved in the immune system activation. Interleukin-10 (IL-10), an important immunoregulatory cytokine, is located on chromosome 1q31-32, a region previously reported to be linked to schizophrenia in genetic studies. In the present study it was aimed to examine the IL-10 gene promoter region's polymorphic variants in patients with schizophrenia in a population of the Elazig Region of East Anatolia, Turkey. Polymorphisms at position -1082, -819 and -592 in the IL-10 promoter region were determined in 171 Turkish patients who were diagnosed with
schizophrenia, based on the DSM-IV, and 168 healthy controls, by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). We analyzed allele, genotype, and haplotype distributions using a case-control association study. Genotyping was performed by RFLP. Statistically significant differences were observed in both allelic and genotypic frequencies of the -592A/C polymorphism (Allele, P=0.034, OR=1.26, 95% CI 1.02-1.56; Genotype, P=0.048), while the other two polymorphisms in distribution of the alleles and genotypes in patients with schizophrenia were not significantly different from those of controls (P>0.05). Our results show a significant increase of GTA homozygotes (the high IL-10-producing haplotype) in schizophrenic patients compared to control subjects
(P=0.0001). These data suggest that the IL-10 gene promoter polymorphism may be one of the susceptibility factors to develop schizophrenia in the Turkish population, and apparently in all humans.
2: J Clin Neurosci 2009 Jan;
Interleukin-5 and interleukin-10 are produced in central nervous system tumor cysts.
[Abstract] Interleukin-5 and interleukin-10, as important mediators of vascular permeability, contribute to the development of various pathologic effusions. However, little is known regarding the involvement of these two cytokines in the formation of cysts associated with central nervous system (CNS) tumors. Twenty-eight patients with various cystic CNS tumors were investigated for expression of interleukin-5 and interleukin-10 in cyst fluid and their matched cytokine receptors in tumor tissue. Interleukin-5 and interleukin-10 were detected in cyst fluid, and interleukin-5 concentration was significantly correlated with interleukin-10 concentration (r=0.508, p=0.006). Moreover, both receptors were also detectable in the tumor tissue specimens and high levels of
expression were also found in perivascular cells. Therefore, the local production of interleukin-5 and interleukin-10 might be implicated in some types of cyst formation.
3: World J Urol 2009 Jan;
IL-10 -1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort.
[Abstract] BACKGROUND: Chronic intraprostatic inflammation is suspected to play a major role in the pathogenesis of prostate cancer (PCa). Polymorphisms in interleukin-10 (IL-10), a key anti-inflammatory cytokine gene can influence immune response and immune evasion of tumor cells. Its role as an anti-metastatic molecule is also well documented. METHODS: Gene promoter polymorphisms in IL-10 (-1082 G>A and -819 C>T) was analyzed in 159 PCa patients and 259 healthy controls to investigate their potential association with susceptibility for PCa. RESULTS: Our results indicated that the heterozygous (GA) and homozygous mutant (AA) genotypes of IL-10 -1082 to be more prevalent among PCa patients in comparison to controls (GA: OR - 2.8, p = 0.011; AA: OR - 2.3, p = 0.037). More
patients (92.5%) than controls (82.7%) were positive for the A allele (GA + AA: OR - 2.6, p = 0.015). We observed lower frequency of T(-819)-G(-1082) haplotype in patients without bone metastasis (4.4%, OR - 0.30, p = 0.019) in comparison to PCa patients with bone metastasis (12.6%). CONCLUSION: Our results support the emerging hypothesis that genetically determined immune activity may play a role in the pathophysiology of PCa. Our findings of high producer of IL-10 -1082 variants suggest initiation of PCa. Future studies in large cohort of different ethnicity PCa groups are warranted to establish definite associations with other cytokine gene polymorphisms.
4: Scand J Immunol 2008
Genetically Engineered Lactococcus lactis Secreting Murine IL-10 Modulates the Functions of Bone Marrow-Derived Dendritic Cells in the Presence of LPS.
[Abstract] Abstract Oral delivery of IL-10 by genetically modified Lactococcus lactis (LL-pTmIL10) has been shown to efficiently reduce intestinal inflammation in mice with chronic colitis, but the mechanisms involved have not been elucidated. It has been suggested that IL-10 controls intestinal inflammation by inhibiting microbe-induced activation of dendritic cells. We therefore investigated whether LL-pTmIL10 can modulate the functions of bone marrow-derived dendritic cells (BM-DC) responding to LPS. Incubation of these cells with LL-pTmIL10 or with the control strain LL-pTREX reduced their ability to activate allogeneic T-cell proliferation. However, in contrast to LL-pTREX, LL-pTmIL10 inhibited the LPS-stimulated secretion of MCP-1 by BM-DC and reduced the
synergistic up-regulation of IL-12/IL-23p40. In addition, LL-pTmIL10 treatment of LPS-stimulated BM-DC significantly inhibited their capacity to induce strong secretion of IL-17 by CD4(+) T cells. Our data suggest that the beneficial effects of LL-pTmIL10 treatment during chronic colitis might involve inhibition of CD4(+) Th17 cells and a reduced accumulation of these cells as well as other immune cells at the site of inflammation.
Protein Accession No.:
SPGQG TQSEN SCTHF PGNLP NMLRD LRDAF SRVKT FFQMK DQLDN LLLKE SLLED FKGYL GCQAL SEMIQ FYLEE VMPQA ENQDP DIKAH VNSLG ENLKT LRLRL RRCHR FLPCE NKSKA VEQVK NAFNK LQEKG IYKAM SEFDI FINYI EAYMT MKIRN
*NOTE: ALL PRODUCTS ARE FOR RESEARCH USE ONLY